European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion

Journal of Clinical Oncology

Volumn 12, Issue 12, 1994, Pages 2654-2666

  Eisenhauer, Elizabeth A ^a   Ten Bokkel Huinink, Wim W ^b   Swenerton, Kenneth D ^b   Gianni, Luca ^b   Myles, James ^b   Van Der Burg, Maria E L ^b   Kerr, Ian ^b   Vermorken, Jan B ^b   Buser, Katharina ^b   Colombo, Nicoletta ^b   Bacon, Monica ^b   Santabárbara, Pedro ^b   Onetto, Nicole ^b   Winograd, Benjamin ^b   Canetta, Renzo ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; HEMOGLOBIN; PACLITAXEL; RANITIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANADA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; DRUG SAFETY; EUROPE; GRANULOCYTOPENIA; HAIR LOSS; HUMAN; HYPERSENSITIVITY REACTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VOMITING;

EID: 0027999966     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.12.2654     Document Type: Article

References (21)

1. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
2. Weiss R, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
3. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
4. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
5. Thigpen T, Blessing J, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol 12:1748-1753, 1994
6. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and schedule issues in the development of paclitaxel (Taxol®). Semin Oncol 20:31-39, 1993 (suppl 3)
7. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
8. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
9. Kearns C, Gianni L, Vigano L, et al: Non-linear pharmacokinetics of Taxol in humans. J Clin Oncol (in press)
10. Spitzer WO, Dobson AJ, Hall J, et al: Measuring the quality of life of cancer patients. J Chronic Dis 34:585-598, 1981
11. Sarosy G, Kohn E, Link C, et al: Dose intensity: Is there a dose-response relationship for Taxol? Proceedings of the Second National Cancer Institute Workshop on Taxol and Taxus, Alexandria, VA, September 22-24, 1992
12. Gelmon K, Nabholtz JM, Bontenbal M, et al: Randomized trial of two doses of Taxol™ (paclitaxel) in metastatic breast cancer after failure of standard therapy. Ann Oncol 5:198, 1994 (suppl 5, abstr 493)
13. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
14. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst monograph 15:47-53, 1993
15. Gore ME, Fryatt I, Wilshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211, 1990
16. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
17. Blackledge G, Lawton F, Redman C, et al: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 59:650-653, 1989
18. Neijt JP: Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 3:17-27, 1992
19. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 303:884-893, 1991
20. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
21. McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/Taxol (PT) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 12:255, 1993 (abstr 808)